Literature DB >> 33597619

Low-coverage whole-genome sequencing of extracellular vesicle-associated DNA in patients with metastatic cancer.

Bella Nguyen1,2, Nicholas C Wong3, Tim Semple4, Michael Clark5, Stephen Q Wong4, Connull Leslie6,7, Bob Mirzai2,7, Michael Millward1,8, Katie Meehan9, Annette M Lim10.   

Abstract

Low-coverage whole-genome sequencing (LC-WGS) can provide insight into oncogenic molecular changes. Serum extracellular vesicles (EV) represent a novel liquid biopsy source of tumoral DNA. This study compared copy number alteration (CNA) profiles generated from LC-WGS of formalin-fixed paraffin-embedded (FFPE) tumoral DNA and EV-DNA obtained from cancer patients. Patients with squamous cell carcinoma of the base of tongue (n = 3) and cutaneous squamous cell carcinoma (n = 2) were included. LC-WGS (0.5-1X coverage) was performed on FFPE-DNA and serum EV-DNA. Similarity between CNA profiles was analysed using QDNAseq. FFPE samples had a mean CNA of 31 (range 17-50) over 1.9 × 109 (range 1.0-2.6 × 109) bp in length, and EV samples had a mean CNA value of 17 (range 7-19) over 7.6 × 108 (range 2.9-15 × 108) bp in length. A mean of 8 (range 0-21) CNA over 5.9 × 108 (range 1.6-14 × 108) bp in length was found to overlap between EV and FFPE-derived samples per patient. Although the mean correlation efficient between samples was r = 0.34 (range - .08 to 0.99), this was not statistically significant (p > 0.05). Regions of highest deletion and duplication in FFPE samples were not well reflected in the EV-DNA. Selected CNA regions in EV-associated DNA were reflective of the primary tumor, however appreciation of global CNA and areas of most significant change was lost. The utility of LC-WGS of EV-derived DNA is likely limited to molecular alterations of known interest.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33597619      PMCID: PMC7889887          DOI: 10.1038/s41598-021-83436-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  44 in total

1.  Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.

Authors:  J Castillo; V Bernard; F A San Lucas; K Allenson; M Capello; D U Kim; P Gascoyne; F C Mulu; B M Stephens; J Huang; H Wang; A A Momin; R O Jacamo; M Katz; R Wolff; M Javle; G Varadhachary; I I Wistuba; S Hanash; A Maitra; H Alvarez
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

2.  Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients.

Authors:  Taylor J Jensen; Aaron M Goodman; Shumei Kato; Christopher K Ellison; Gregory A Daniels; Lisa Kim; Prachi Nakashe; Erin McCarthy; Amin R Mazloom; Graham McLennan; Daniel S Grosu; Mathias Ehrich; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2018-12-06       Impact factor: 6.261

Review 3.  Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies.

Authors:  Ellen Heitzer; Peter Ulz; Jochen B Geigl; Michael R Speicher
Journal:  Mol Oncol       Date:  2015-12-17       Impact factor: 6.603

4.  Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.

Authors:  Shu Xia; Chiang-Ching Huang; Min Le; Rachel Dittmar; Meijun Du; Tiezheng Yuan; Yongchen Guo; Yuan Wang; Xuexia Wang; Susan Tsai; Saul Suster; Alexander C Mackinnon; Liang Wang
Journal:  Lung Cancer       Date:  2015-07-15       Impact factor: 5.705

5.  Exosomes: Potential in Cancer Diagnosis and Therapy.

Authors:  Phillip Munson; Arti Shukla
Journal:  Medicines (Basel)       Date:  2015-11-02

6.  KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population.

Authors:  Yi-Xin Hao; Yong-Mei Li; Ming Ye; Yan-Yan Guo; Qiu-Wen Li; Xiu-Mei Peng; Qi Wang; Shu-Fang Zhang; Hui-Xia Zhao; He Zhang; Guang-Hui Li; Jian-Hua Zhu; Wen-Hua Xiao
Journal:  Oncol Lett       Date:  2017-03-22       Impact factor: 2.967

Review 7.  Potential Role of Serum and Urinary Biomarkers in Diagnosis and Prognosis of Diabetic Nephropathy.

Authors:  Carole G Campion; Oraly Sanchez-Ferras; Sri N Batchu
Journal:  Can J Kidney Health Dis       Date:  2017-05-22

8.  High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays.

Authors:  Yuker Wang; Victoria E H Carlton; George Karlin-Neumann; Ronald Sapolsky; Li Zhang; Martin Moorhead; Zhigang C Wang; Andrea L Richardson; Robert Warren; Axel Walther; Melissa Bondy; Aysegul Sahin; Ralf Krahe; Musaffe Tuna; Patricia A Thompson; Paul T Spellman; Joe W Gray; Gordon B Mills; Malek Faham
Journal:  BMC Med Genomics       Date:  2009-02-19       Impact factor: 3.063

9.  Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.

Authors:  Daniel H Hovelson; Chia-Jen Liu; Yugang Wang; Qing Kang; James Henderson; Amy Gursky; Scott Brockman; Nithya Ramnath; John C Krauss; Moshe Talpaz; Malathi Kandarpa; Rashmi Chugh; Missy Tuck; Kirk Herman; Catherine S Grasso; Michael J Quist; Felix Y Feng; Christine Haakenson; John Langmore; Emmanuel Kamberov; Tim Tesmer; Hatim Husain; Robert J Lonigro; Dan Robinson; David C Smith; Ajjai S Alva; Maha H Hussain; Arul M Chinnaiyan; Muneesh Tewari; Ryan E Mills; Todd M Morgan; Scott A Tomlins
Journal:  Oncotarget       Date:  2017-09-22

10.  Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder.

Authors:  Dong Hyeon Lee; Hana Yoon; Sanghui Park; Jeong Seon Kim; Young-Ho Ahn; Kihwan Kwon; Donghwan Lee; Kwang Hyun Kim
Journal:  Sci Rep       Date:  2018-10-02       Impact factor: 4.379

View more
  1 in total

1.  Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients.

Authors:  Mareike Waldenmaier; Lucas Schulte; Jonathan Schönfelder; Axel Fürstberger; Johann M Kraus; Nora Daiss; Tanja Seibold; Mareen Morawe; Thomas J Ettrich; Hans A Kestler; Christoph Kahlert; Thomas Seufferlein; Tim Eiseler
Journal:  Cancers (Basel)       Date:  2022-02-21       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.